Tango Therapeutics
Update in progressTNGX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tango Therapeutics is a precision oncology company focused on discovering and developing drugs for defined patient populations with unmet needs. It is advancing methylthioadenosine (MTAP)-cooperative PRMT5 inhibitors, including TNG462 in a Phase 1/2 trial for pancreatic and lung cancer, and TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma. It is also developing TNG260, a REST co-repressor to counter STK11 loss-driven immune evasion in lung cancer. Founded in 2017 and based in Boston.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!